Physician profile
Devendra K Shrivastava
NPI 1952494536
$3,446.35
in general payments reported to CMS, 2019-2025
22 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $337 · 2021: $510 · 2022: $849 · 2023: $288 · 2024: $621 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $535.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $440.28 | 2020-2025 | Nucala |
| Boston Scientific Corporation | $369.21 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $360.87 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $356.91 | 2019-2024 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $206.15 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $171.55 | 2019 | |
| Vifor Pharma, INC. | $148.82 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $139.36 | 2022-2023 | Jynarque |
| Xeris Pharmaceuticals, INC. | $125.05 | 2024 | Gvoke Hypopen |
| Gilead Sciences, INC. | $83.63 | 2019 | |
| Ardelyx, INC. | $81.43 | 2025 | Ibsrela |
| Akebia Therapeutics INC | $79.55 | 2020-2025 | Auryxia, Vafseo |
| Intuitive Surgical, INC. | $75.96 | 2023 | Da Vinci Surgical System |
| Amgen INC. | $74.30 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $58.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $30.00 | 2024 | |
| Lilly USA, LLC | $24.60 | 2022 | |
| Cormedix INC. | $17.15 | 2025 | Defencath |
| Novo Nordisk INC | $17.14 | 2021 | |
| Merck Sharp & Dohme LLC | $13.75 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Shrivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.